1. Pink Sheet

Xtandi Petition Will Give Biden Administration Chance To Weigh In On Pricing, March-In Rights

 
• By Brenda Sandburg

Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.

March-in
Prostate cancer pateints want HHS to march-in and take rights to Xtandi patents • Source: Alamy

After striking out with previous administrations, petitioners backed by Knowledge Ecology International are once again asking the Department of Health and Human Services to grant march-in rights to Xtandi patents given the high price of the prostate cancer drug in the US. This is the first march-in case to come before the Biden Administration, which will test whether it supports using this mechanism to address drug pricing.

At a 15 December press briefing, KEI Director James Love said petitioners have asked HHS to conduct an administrative hearing to determine whether or not the approximately $156,000 annual cost of Astellas Pharma, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.